Total Payments
$917,994
2024 Payments
$33,106
Companies
46
Transactions
1,229
Medicare Patients
5,351
Medicare Billing
$1.0M
Payment Breakdown by Category
Research$878,771 (95.7%)
Food & Beverage$21,773 (2.4%)
Consulting$8,009 (0.9%)
Travel$7,929 (0.9%)
Other$1,500 (0.2%)
Education$11.49 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $878,771 | 175 | 95.7% |
| Food and Beverage | $21,773 | 1,031 | 2.4% |
| Consulting Fee | $8,009 | 2 | 0.9% |
| Travel and Lodging | $7,929 | 18 | 0.9% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1,500 | 1 | 0.2% |
| Education | $11.49 | 2 | 0.0% |
Payments by Type
Research
$878,771
175 transactions
General
$39,222
1,054 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| SANOFI US SERVICES INC. | $266,520 | 60 | $0 (2024) |
| Theravance Biopharma, Inc. | $256,522 | 35 | $0 (2018) |
| GENZYME CORPORATION | $188,199 | 113 | $0 (2024) |
| Genentech, Inc. | $51,943 | 11 | $0 (2020) |
| Teva Pharmaceuticals USA, Inc. | $41,319 | 50 | $0 (2023) |
| AstraZeneca UK Limited | $23,311 | 2 | $0 (2017) |
| Eli Lilly and Company | $20,730 | 2 | $0 (2020) |
| Mylan Specialty L.P. | $17,482 | 13 | $0 (2023) |
| Roche Products Limited | $9,542 | 3 | $0 (2017) |
| Circassia Pharmaceuticals Inc | $8,038 | 4 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $33,106 | 142 | SANOFI US SERVICES INC. ($29,209) |
| 2023 | $10,377 | 168 | Chiesi USA, Inc. ($4,290) |
| 2022 | $38,429 | 146 | GENZYME CORPORATION ($17,849) |
| 2021 | $133,193 | 166 | GENZYME CORPORATION ($104,941) |
| 2020 | $89,888 | 109 | GENZYME CORPORATION ($64,204) |
| 2019 | $19,007 | 138 | Mylan Specialty L.P. ($10,136) |
| 2018 | $224,063 | 171 | Theravance Biopharma, Inc. ($107,615) |
| 2017 | $369,930 | 189 | Theravance Biopharma Inc. ($148,907) |
All Payment Transactions
1,229 individual payment records from CMS Open Payments — Page 1 of 50
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | Genentech USA, Inc. | Xolair (Biological) | Food and Beverage | In-kind items and services | $25.03 | General |
| Category: Immunology | ||||||
| 12/18/2024 | Genentech USA, Inc. | Xolair (Biological) | Food and Beverage | In-kind items and services | $2.43 | General |
| Category: Immunology | ||||||
| 12/17/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $17.12 | General |
| Category: IMMUNOLOGY | ||||||
| 12/16/2024 | CSL Behring | Haegarda (Biological) | Food and Beverage | In-kind items and services | $16.86 | General |
| Category: Immunology | ||||||
| 12/13/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Food and Beverage | In-kind items and services | $27.51 | General |
| Category: Respiratory | ||||||
| 12/11/2024 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Food and Beverage | In-kind items and services | $17.39 | General |
| Category: Respiratory | ||||||
| 12/11/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug), AREXVY | Food and Beverage | In-kind items and services | $12.04 | General |
| Category: RESPIRATORY | ||||||
| 12/05/2024 | CSL Behring | Hizentra (Biological) | Food and Beverage | In-kind items and services | $21.00 | General |
| Category: Immunology | ||||||
| 12/04/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $35.96 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/03/2024 | Grifols USA, LLC | Prolastin-C Liquid (Biological) | Food and Beverage | In-kind items and services | $20.42 | General |
| Category: Pulmonology | ||||||
| 11/26/2024 | CSL Behring | Haegarda (Biological) | Food and Beverage | In-kind items and services | $22.59 | General |
| Category: Immunology | ||||||
| 11/25/2024 | Optinose US, Inc. | Xhance (Drug) | Food and Beverage | In-kind items and services | $18.20 | General |
| Category: Otolaryngology (Ear, Nose, Throat) | ||||||
| 11/22/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $19.10 | General |
| Category: RESPIRATORY | ||||||
| 11/21/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $37.07 | General |
| Category: Immunology | ||||||
| 11/20/2024 | CSL Behring | Hizentra (Biological) | Food and Beverage | In-kind items and services | $18.07 | General |
| Category: Immunology | ||||||
| 11/18/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Food and Beverage | In-kind items and services | $20.74 | General |
| Category: Respiratory | ||||||
| 11/11/2024 | Octapharma USA, Inc. | PANZYGA (Biological) | Food and Beverage | In-kind items and services | $88.77 | General |
| Category: IMMUNOLOGY | ||||||
| 11/11/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $13.19 | General |
| Category: Respiratory | ||||||
| 11/08/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Food and Beverage | In-kind items and services | $19.00 | General |
| Category: Respiratory | ||||||
| 11/07/2024 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Food and Beverage | In-kind items and services | $18.20 | General |
| Category: Respiratory | ||||||
| 11/04/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $20.78 | General |
| Category: IMMUNOLOGY | ||||||
| 11/04/2024 | Grifols USA, LLC | Xembify (Biological) | Food and Beverage | In-kind items and services | $18.98 | General |
| Category: Immunology and Neurology | ||||||
| 10/30/2024 | CSL Behring | Haegarda (Biological) | Food and Beverage | In-kind items and services | $24.24 | General |
| Category: Immunology | ||||||
| 10/29/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $42.09 | General |
| Category: Immunology | ||||||
| 10/28/2024 | CSL Behring | Hizentra (Biological) | Food and Beverage | In-kind items and services | $18.55 | General |
| Category: Immunology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Asthma dupilumab | SANOFI US SERVICES INC. | $145,627 | 26 |
| A Randomized Double-blind, Placebo-controlled Study Evaluating the Effect of Dupilumab on Sleep in Adult Patients With Moderate to Severe Atopic Dermatitis (AD) | GENZYME CORPORATION | $133,319 | 30 |
| 0128 TD-4208 | Theravance Biopharma Inc. | $114,984 | 13 |
| 28-day Parallel Group Safety Study of Revefenacin in COPD | Theravance Biopharma, Inc. | $84,446 | 4 |
| Asthma Dupilumab | SANOFI US SERVICES INC. | $59,999 | 14 |
| Master Protocol of Two Randomized, Double-blind, Placebo Controlled, Multi-center, Parallel-group Studies of Dupilumab in Patients With Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite the Use of H1 Antihistamine Treatment in Patients naive to Omalizumab and in Patients Who Are Intolerant or Incomplete Responders to Omalizumab | SANOFI US SERVICES INC. | $56,880 | 16 |
| A Phase 4, Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study of the Effect of Dupilumab on Sleep Disturbance in Patients With Uncontrolled Persistent Asthma | GENZYME CORPORATION | $53,010 | 14 |
| 0149_PIFR | Theravance Biopharma Inc. | $32,516 | 7 |
| STUDY2 PATIENTS UNCONTROLLED ON ICS 2ND CONTROLLER | Genentech, Inc. | $28,418 | 7 |
| XTEND CIU | Genentech, Inc. | $23,525 | 4 |
| This is a multiple dose randomized parallel double blind double dummy multicenter and multinational Phase III study to determine the efficacy and safety of Aclidinium bromide 400 Formoterol Fumarate AB FF 12 compared to individual components and Tiotropium 18 when administered to patients with stable chronic obstructive pulmonary disease COPD | AstraZeneca UK Limited | $23,311 | 2 |
| ABS-AS-30064 | Teva Pharmaceuticals USA, Inc. | $22,397 | 6 |
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 CROSSOVER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3454738 IN ADULTS WITH CHRONIC SPONTANEOUS URTICARIA INADEQUATELY CONTROLLED WITH H1-ANTIHISTAMINES | Eli Lilly and Company | $20,730 | 2 |
| Research_A Phase 3b, 28-day, Randomized, Active-Controlled, Parallel Group Study to Evaluate the Safety and Tolerability of Nebulized Revefenacin administered before Nebulized Formoterol Fumarate (PER | Mylan Specialty L.P. | $10,097 | 1 |
| ADOLESCENT PATIENTS WITH SEVERE ASTHMA | Roche Products Limited | $9,542 | 3 |
| Phase 3b 28-day Randomized Active Controlled Parallel Group Study to Evaluate the Safety and Tolerability of Nebulized Revefenancin | Theravance Biopharma, Inc. | $9,194 | 1 |
| Phase 3 Randomized Double-Blind Double-Dummy Parallel-Group Study to Compare Once Daily Nebulized Revefenacin with Spiriva | Theravance Biopharma, Inc. | $8,494 | 2 |
| A Double-Blind, Randomised, Placebo-Controlled, Multi-Centre Field Study to Assess the Efficacy and Safety of HDM-SPIRE in Subjects With a History of House Dust Mite-Induced Rhinoconjunctivitis | Circassia Pharmaceuticals Inc | $7,995 | 1 |
| CONNected Electronic Inhalers Asthma Control Trial 1 ("CONNECT 1"), a 12-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study to Evaluate the Effectiveness of the Albuterol eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma | Teva Pharmaceuticals USA, Inc. | $7,736 | 3 |
| Research_Phase 3b, 28-day, Randomized, Active-Controlled, Parallel Group Study to Evaluate Safety and Tolerability of Nebulized Revefenacin administered before Nebulized Formoterol Fumarate | Mylan Specialty L.P. | $5,703 | 1 |
| Phase 3b, 28-day, Randomized, Active-Controlled, Parallel Group Study to Evaluate Safety and Tolerability of Nebulized Revefenacin adminstersed before Nebulized Formoterol Fumarate | Theravance Biopharma, Inc. | $5,480 | 3 |
| BDB-AS-302 | Teva Pharmaceuticals USA, Inc. | $4,556 | 2 |
| Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Dupilumab in Patients With Asthma Who Participated in a Previous Dupilumab Asthma Clinical Study | SANOFI US SERVICES INC. | $4,013 | 4 |
| A 12-Week, Open-Label Study to Evaluate the Relationship Between Use of Albuterol eMDPI, an Inhaled Short-Acting Beta Agonist "Rescue" Agent With an eModule, and Exacerbations in Patients (18 Years of Age or Older) With Asthma | Teva Pharmaceuticals USA, Inc. | $3,469 | 4 |
| CONNected Electronic Inhalers Asthma Control Trial 2 ("CONNECT 2"), a 24-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study of Standard of Care Treatment Versus the eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma | Teva Pharmaceuticals USA, Inc. | $2,545 | 3 |
| CLOU064A2301- REMIX-1,CLOU064A2302-REMIX-2 | Novartis Pharmaceuticals Corporation | $580.28 | 1 |
| A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent HFA 110 mcg, in Adult Subjects With Asthma | Teva Pharmaceuticals USA, Inc. | $204.98 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 17 | 1,343 | 11,005 | $336,399 | $240,757 |
| 2022 | 19 | 1,438 | 12,904 | $390,540 | $284,089 |
| 2021 | 15 | 1,223 | 10,237 | $299,692 | $221,856 |
| 2020 | 15 | 1,347 | 13,366 | $347,528 | $255,257 |
Total Patients
5,351
Total Services
47,512
Medicare Billing
$1.0M
Procedure Codes
66
All Medicare Procedures & Services
66 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J2357 | Injection, omalizumab, 5 mg | Office | 2023 | 14 | 3,210 | $128,400 | $96,857 | 75.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 453 | 677 | $78,115 | $54,252 | 69.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 196 | 196 | $32,825 | $22,324 | 68.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 139 | 215 | $16,273 | $11,809 | 72.6% |
| 95165 | Professional service for preparation and provision of 1 or more antigens | Office | 2023 | 46 | 900 | $12,852 | $9,487 | 73.8% |
| 95004 | Test for allergy using allergenic extract | Office | 2023 | 69 | 3,097 | $13,400 | $8,415 | 62.8% |
| 95024 | Test for allergy using allergenic extract injected into skin | Office | 2023 | 61 | 1,198 | $9,648 | $7,162 | 74.2% |
| 95018 | Test for allergy using combination of methods with drug or biological | Office | 2023 | 42 | 417 | $8,764 | $6,161 | 70.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 43 | 43 | $9,088 | $6,100 | 67.1% |
| 95180 | Injection for rapid desensitization to allergen | Office | 2023 | 38 | 56 | $7,888 | $5,827 | 73.9% |
| 95076 | Test for allergy using ingested items, initial 2 hours | Office | 2023 | 44 | 46 | $5,543 | $3,884 | 70.1% |
| 95117 | Professional service for multiple injections of allergen | Office | 2023 | 44 | 369 | $4,265 | $2,519 | 59.0% |
| 95115 | Professional service for single injection of allergen | Office | 2023 | 40 | 366 | $3,341 | $2,082 | 62.3% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 25 | 125 | $1,769 | $1,363 | 77.0% |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | Office | 2023 | 49 | 50 | $2,928 | $1,244 | 42.5% |
| 90662 | Influenza vaccine split virus, preservative free | Office | 2023 | 20 | 20 | $700.00 | $686.00 | 98.0% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 20 | 20 | $600.00 | $588.00 | 98.0% |
| J2357 | Injection, omalizumab, 5 mg | Office | 2022 | 16 | 4,471 | $178,840 | $133,379 | 74.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 404 | 585 | $67,437 | $47,920 | 71.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 243 | 243 | $40,692 | $27,597 | 67.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 194 | 274 | $20,720 | $15,383 | 74.2% |
| 95004 | Test for allergy using allergenic extract | Office | 2022 | 79 | 3,493 | $15,225 | $10,433 | 68.5% |
| 95165 | Professional service for preparation and provision of 1 or more antigens | Office | 2022 | 50 | 955 | $13,635 | $10,040 | 73.6% |
| 95024 | Test for allergy using allergenic extract injected into skin | Office | 2022 | 66 | 1,326 | $10,686 | $8,284 | 77.5% |
| 95018 | Test for allergy using combination of methods with drug or biological | Office | 2022 | 31 | 313 | $6,589 | $4,874 | 74.0% |
About Dr. Hugh Windom, M.D
Dr. Hugh Windom, M.D is a Allergy healthcare provider based in Sarasota, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/14/2005. The National Provider Identifier (NPI) number assigned to this provider is 1013902204.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Hugh Windom, M.D has received a total of $917,994 in payments from pharmaceutical and medical device companies, with $33,106 received in 2024. These payments were reported across 1,229 transactions from 46 companies. The most common payment nature is "" ($878,771).
As a Medicare-enrolled provider, Windom has provided services to 5,351 Medicare beneficiaries, totaling 47,512 services with total Medicare billing of $1.0M. Data is available for 4 years (2020–2023), covering 66 distinct procedure/service records.
Ad
Practice Information
- Specialty Allergy
- Location Sarasota, FL
- Active Since 09/14/2005
- Last Updated 03/06/2014
- Taxonomy Code 207KA0200X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1013902204
Products in Payments
- DUPIXENT (Biological) $245,763
- NO PRODUCT DISCUSSED (Drug) $205,626
- Non-Covered Product (Drug) $37,960
- Xolair (Biological) $24,247
- ProAir (Drug) $22,397
- Yupelri (Drug) $17,383
- Albuterol Sulfate (Drug) $10,281
- PALFORZIA (Biological) $8,023
- QVAR (Drug) $4,654
- DUPIXENT (Drug) $4,190
- ProAir HFA (Drug) $3,469
- CUTAQUIG (Biological) $1,657
- Dust mite (D. farinae) (Biological) $1,531
- NUCALA (Biological) $1,130
- Haegarda (Biological) $1,107
- TAKHZYRO (Biological) $1,106
- TRELEGY ELLIPTA (Drug) $752.62
- AUVI-Q (Drug) $726.98
- FASENRA (Biological) $712.74
- TEZSPIRE (Biological) $695.42
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.